Geriatrics

Data from 2 phase 3 trials, which included more than 1800 patients, examining the efficacy and safety profile of abicipar for the treatment of neovascular age-related macular degeneration were presented at AAO 2019.

Data from a phase 1/2a study show RGX-314, a gene therapy from RegenX, was well tolerated and improved visual acuity in patients.

Results of the phase 1 OPTIC trial reveal ADVM-022 was effective at maintaining visual acuity in patients with wet AMD with a favorable safety profile.

The CDC Influenza Division medical director reported new findings at IDWeek showing older patients with influenza subtype A were more likely to be hospitalized.

In an extensive analysis, investigators link antipsychotic initiators with more days in the hospital for Alzheimer disease patients.

Novartis has announced the wet age-related macular degeneration treatment brolucizumab, which was backed by data from the HAWK and HARRIER trials, has received FDA approval.

In a new trial, investigators test whether continuing or discontinuing ADA is more beneficial.

Investigators find zolpidem effectively reduces suicidal ideation, particularly for patients suffering from severe insomnia symptoms.

More than 90% of those surveyed report poor sleep quality impacts the next day negatively.

A recent study into insulin use in adults 75 and older found insulin use was increased in those with worse health, indicating a lack of adherence to current guideline recommendations.

There are many factors that make living at home with Alzheimer disease difficult.

In an intervention study, investigators try to show whether vitamin D deficiency interferes with slowing muscle wasting and losing function in geriatric adults.

A study from Brigham and Women's Hospital found asking clinicians if they would be surprised if older patients would die in the next month could save patients money on healthcare and improve quality of end-of-life care.

The aim of the “Alzheimer’s Disease Exposome” will be to identify new interactions of risk genes for future studies.

A group of 370 leading healthcare organizations have sent a letter to congress in support of a bipartisan bill that would protect Medicare Advantage Beneficiaries from delays caused by prior authorizations.

Acadia Pharmaceuticals has announced positive findings for time to psychosis relapse in dementia patients, which resulted in the trial's early end.